Canine Fatty Tumor

Breast cancer refers to cancers originating from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk. Cancers originating from ducts are known as ductal carcinomas; those originating from lobules are known as lobular carcinomas. There are many different types of breast cancer, with different stages (spread), aggressiveness, and genetic makeup; survival varies greatly depending on those factors. Computerized models are available to predict survival. With best treatment and dependent on staging, 10-year disease-free survival varies from 98% to 10%. Treatment includes surgery, drugs (hormonal therapy and chemotherapy), and radiation.

Worldwide, breast cancer comprises 10.4% of all cancer incidence among women, making it the second most common type of non-skin cancer (after lung cancer) and the fifth most common cause of cancer death. In 2004, breast cancer caused 519,000 deaths worldwide (7% of cancer deaths; almost 1% of all deaths). Breast cancer is about 100 times more common in women than in men, but survival rates are equal in both sexes.

Some breast cancers require the hormones estrogen and progesterone to grow, and have receptors for those hormones. After surgery those cancers are treated with drugs that interfere with those hormones, usually tamoxifen, and with drugs that shut off the production of estrogen in the ovaries or elsewhere; this may damage the ovaries and end fertility. After surgery, low-risk, hormone-sensitive breast cancers may be treated with hormone therapy and radiation alone. Breast cancers without hormone receptors, or which have spread to the lymph nodes in the armpits, or which express certain genetic characteristics, are higher-risk, and are treated more aggressively. One standard regimen, popular in the U.S., is cyclophosphamide plus doxorubicin (Adriamycin), known as CA; these drugs damage DNA in the cancer, but also in fast-growing normal cells where they cause serious side effects. Sometimes a taxane drug, such as docetaxel, is added, and the regime is then known as CAT; taxane attacks the microtubules in cancer cells. An equivalent treatment, popular in Europe, is cyclophosphamide, methotrexate, and fluorouracil (CMF). Monoclonal antibodies, such as trastuzumab (Herceptin), are used for cancer cells that have the HER2 mutation. Radiation is usually added to the surgical bed to control cancer cells that were missed by the surgery, which usually extends survival, although radiation exposure to the heart may cause damage and heart failure in the following years.

Classification

Main article: Breast cancer classification

Breast cancers can be classified by different schemata. They include stage (TNM), pathology, grade, receptor status, and the presence or absence of genes as determined by DNA testing:

  • Stage. The TNM classification for breast cancer is based on the size of the tumor (T), whether or not the tumor has spread to the lymph nodes (N) in the armpits, and whether the tumor has metastasized (M) or spread to a more distant part of the body. Larger size, nodal spread, and metastasis have a larger stage number and a worse prognosis.
    The main stages are:
    Stage Tis is Carcinoma In Situ (eg DCIS), a pre-malignant disease or marker.
    Stages 1-3 are defined as 'early' cancer and potentially curable.
    Stage 4 is defined as 'advanced' cancer and incurable.
  • Pathology. Most breast cancers are' derived from the epithelium lining the ducts or lobules. (Cancers from other tissues are considered "rare" cancers.) Carcinoma in situ is proliferation of cancer cells within the epithelial tissue without invasion of the surrounding tissue. Invasive carcinoma invades the surrounding tissue. Cells that are dividing more quickly have a worse prognosis. One way to measure tumor cell growth is with the presence of protein Ki67, which indicates that the cell is in S phase, and also indicates susceptibility to certain treatments.
  • Grade (Bloom-Richardson grade). When cells become differentiated, they take different shapes and forms to function as part of an organ. Cancerous cells lose that differentiation. Cells that normally line up in an orderly way to make up the milk ducts become disorganized. Cell division becomes uncontrolled. Cell nuclei become less uniform. Pathologists describe cells as well differentiated (low grade), moderately differentiated (intermediate grade), and poorly differentiated (high grade). Poorly-differentiated cancers have a worse prognosis.
  • Receptor status. Cells have receptors on their surface and in their cytoplasm and nucleus. Chemical messengers such as hormones bind to receptors, and this causes changes in the cell. Breast cancer cells may or may not have three important receptors: estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. Cells with these receptors are called ER positive (ER+), ER negative (ER-), PR positive (PR+), PR negative (PR-), HER2 positive (HER2+), and HER2 negative (HER2-). Cells with none of these receptors are called basal-like or triple negative. ER+ cancer cells depend on estrogen for their growth, so they can be treated with drugs to reduce estrogen (eg tamoxifen), and generally have a better prognosis.
    Generally, HER2+ had a worse prognosis, however HER2+ cancer cells respond to drugs such as the monoclonal antibody, trastuzumab, (in combination with conventional chemotherapy) and this has improved the prognosis significantly.
    All of these receptors are identified by immunohistochemistry.
    Receptor status is used to divide breast cancer into four molecular classes: (1) Basal-like, which are ER-, PR- and HER2- (triple negative, TN). Most BRCA1 breast cancers are basal-like TN. (2) Luminal A, which are ER+ and low grade (3) Luminal B, which are ER+ but often high grade (4) HER2+, which have amplified ERBB2.
    Finally, receptor status has become a critical assessment for all breast cancers, as it determines the suitability of using targeted treatments eg tamoxifen and or trastuzumab. These treatments are now some of the most effective adjuvant treatments of breast cancer. Conversely, triple negative cancer (ie no positive receptors) is now thought to indicate a poor prognosis.
  • DNA microarrays have compared normal cells to breast cancer cells and found differences in hundreds of genes, but the significance of most of those differences is unknown. Several screening tests are commercially marketed, but the evidence for their value is limited. The only test supported by Level II evidence is Oncotype DX, which is not approved by the U.S. Food and Drug Administration (FDA) but is endorsed by the American Society of Clinical Oncology. MammaPrint is approved by the FDA but is only supported by Level III evidence. Two other tests have Level III evidence: Theros and MapQuant Dx. No tests have been verified by Level I evidence (in a prospective, randomized controlled trial, patients who used the test had a better outcome than those who did not). In a review, Sotirou concluded, "The genetic tests add modest prognostic information for patients with HER2-positive and triple-negative tumors, but when measures of clinical risk are equivocal (e.g., intermediate expression of ER and intermediate histologic grade), these assays could guide clinical decisions."

Breast cancer is usually, but not always, primarily classified by its histological appearance. Rare variants are defined based on physical exam findings. For example, inflammatory breast cancer (IBC), a form of ductal carcinoma or malignant cancer in the ducts, is distinguished from other carcinomas by the inflamed appearance of the affected breast. In the future, some pathologic classifications may be changed.

Signs and symptoms

The first noticeable symptom of breast cancer is typically a lump that feels different from the rest of the breast tissue. More than 80% of breast cancer cases are discovered when the woman feels a lump. By the time a breast lump is noticeable, it has probably been growing for years. The earliest breast cancers are detected by a mammogram. Lumps found in lymph nodes located in the armpits can also indicate breast cancer.

Indications of breast cancer other than a lump may include changes in breast size or shape, skin dimpling, nipple inversion, or spontaneous single-nipple discharge. Pain ("mastodynia") is an unreliable tool in determining the presence or absence of breast cancer, but may be indicative of other breast health issues.

When breast cancer cells invade the dermal lymphatics—small lymph vessels in the skin of the breast—its presentation can resemble skin inflammation and thus is known as inflammatory breast cancer (IBC). Symptoms of inflammatory breast cancer include pain, swelling, warmth and redness throughout the breast, as well as an orange-peel texture to the skin referred to as peau d'orange .

Another reported symptom complex of breast cancer is Paget's disease of the breast. This syndrome presents as eczematoid skin changes such as redness and mild flaking of the nipple skin. As Paget's advances, symptoms may include tingling, itching, increased sensitivity, burning, and pain. There may also be discharge from the nipple. Approximately half of women diagnosed with Paget's also have a lump in the breast.

Occasionally, breast cancer presents as metastatic disease, that is, cancer that has spread beyond the original organ. Metastatic breast cancer will cause symptoms that depend on the location of metastasis. Common sites of met

External Tumors Lipoma Fatty Tumor canine natural ...

External Tumors Lipoma Fatty Tumor canine natural homeopath herbs

...

Fatty Tumors and Lipomas, from Pet Health 101

Canine hip dysplasia Cat grooming Cat health & behavior facts Cat proof your home ... What is a lipoma (fatty tumor)? A lipoma is one of several different types of skin tumors.

...

Welcome to Web DVM: The Web's Best Source For Canine ...

Lipomas, or fatty tumors as they are often called, occur in just about all breeds of dogs of ... Top Canine & Feline Topics

...

Managing Lipomas (Fatty Tumors) in Dogs

also see Canine Tumors . also see Dog Tumors. Unlike other kinds of tumors, when it comes to fatty tumors dogs are not in any immediate danger. They are very common in older dogs and ...

...

Veterinary Q & A - Lipomas (fatty tumors) in Dogs and ...

Lumps and Bumps in Pets >Lipomas (fatty tumors) in Dogs and Cats. Please see the archive for ... Dry Nose - Health Problem? Canine Pregnancy Parvovirus in Dogs Canine Estrus Cycle

...

The Natural Canine: Lipoma (benign fatty tumor)

Lipoma (li po"m*) is a benign (noncancerous) tumor that is made up of fat cells. Lipomas commonly occur under the skin and may be felt as diffuse, soft swellings, particularly over ...

...

mast cells? fatty tumors? | Dog Forums | DailyPuppy.com

mast cells? fatty tumors? discuss canine health, nutrition, exercise, surgery, injury, illness ... We took him to the vet but were told that they were fatty tumors. Our other ...

...

Fatty Tumors in Dogs

Are you concerned about the soft, fatty lump under the skin of your canine? Don't worry. The lump may just be a benign tumor that is common among old and overweight dogs.

...

How Fatty Tumors in Dogs Develop

also see Fatty Tumors Dogs. also see Dogs Tumors . Fatty tumors in dogs, also known as lipomas ... also see Symptoms of Canine Melanoma. also see Symptoms of Canine Prostate Cancer

...

Canines and Lipomas

Whole Dog Journal contributor Denise Flaim explains canine lipomas, or fatty tumors, rarely cause health problems in dogs. But many holistic practitioners feel they signal an ...

...